For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy
EXPANDED INDICATION ENABLES BROADER USE OF LEQVIO
The FDA has approved the revised indication for use in patients with primary hyperlipidemia
in addition to ESTABLISHED ASCVD and HeFH

Explore the MOA
View to learn more about how LEQVIO works differently than other LDL-C—lowering treatments as a complement to statins.

LEQVIO: From Discovery to Development
View to learn more about how LEQVIO was developed, and its unique features.

Dive Into siRNA Technology
View to learn more about how LEQVIO—a small interfering RNA therapy that selectively targets the liver to regulate LDL-C levels.

How Is LEQVIO Dosing Different From PCSK9 mAbs?
Watch Dr Stephanie J. Saucier, Dr Richard Wright, and Matthew J. Budoff discuss the dosing regimen of LEQVIO and how it may integrate seamlessly into clinical practice.

How Do You Get Your Patients Started on LEQVIO?
Watch Dr Suzanne Shugg, Dr Rajkumar Sugumaran, and Dr Prediman K. Shah discuss the flexible pathways available for acquisition and administration of patients.

LEQVIO via Buy-and-Bill With In-Office Administration
Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method for...

LEQVIO via Referral to an Alternate Injection Center (AIC)
If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle...
What Makes LEQVIO Different
Explore the resources below to dive even further into specific parts of the
LEQVIO story and to see what makes LEQVIO different

LEQVIO: A Bold Way Forward
In this overview presentation, learn about what makes the LEQVIO clinical profile and dosing different

Unmet Need in Patients With ASCVD
Dr Pam Taub and Dr Alan S. Brown provide insights on the state of cardiovascular disease and what makes LEQVIO such a...

Dosing and Administration: How to Give LEQVIO to Your Patients
Dr Alan S. Brown shares details on the LEQVIO dosing regimen—two doses a year after the first year—while highlighting...


LEQVIO: From Discovery to Development
LEQVIO is a small interfering RNA (siRNA) therapy that was studied in clinical trials to assess its efficacy and safety as a...

How Is LEQVIO Dosing Different From PCSK9 mAbs?
Gain valuable insight from experts as they discuss how LEQVIO dosing differs from PCSK9 mAbs.

How Do You Explain the Value of LEQVIO to Your Patients?
Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.
Mechanism of Action
Take a look and become familiar with the LEQVIO mechanism of action


Explore the MOA
LEQVIO—harnessing the natural process of RNAi to lower LDL-C in certain patients with ASCVD on a maximally tolerated statin1


Dive Into siRNA Technology
LEQVIO—a asfsadfasdfsmall interfering RNA therapy that selectively targets the liver to regulate LDL-C levels1

Illustrated MOA
Watch the LEQVIO MOA come to life in this animated video

What's Different About the Way LEQVIO Lowers LDL Cholesterol Compared to PCSK9 mAbs?
LEQVIO is not another PCSK9 monoclonal antibody. It's something else...
Clinical Trial Data: Efficacy & Safety
See what LEQVIO can do for patients like yours

LEQVIO: A Bold Way Forward
In this overview presentation, learn about what makes the LEQVIO clinical profile and dosing different

Lowering LDL-C With LEQVIO: Clinical Trial Data Overview
Dr Alan S. Brown dives deeper into pivotal phase III clinical trial data for LEQVIO for patients with ASCVD, with a focus on...

Recap the LEQVIO Clinical Story On-the-Go
Take a moment for a refresh of the entire LEQVIO clinical story with insights into efficacy, dosing, safety, and more!


ORION-10 Clinical Trial Design
ORION-10 evaluated LDL-C reduction in certain patients with ASCVD1


Discover Clinical Efficacy & Safety
Take a deeper look at data supporting the efficacy and safety of LEQVIO.

How Do You Explain the Value of LEQVIO to Your Patients?
Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.
Access & Acquisition
Gain valuable access and acquisition insight by exploring the videos below

LEQVIO via Specialty Pharmacy
Gain insights into a third acquisition option for patients to acquire LEQVIO: a specialty pharmacy for in-office administration

LEQVIO via Buy-and-Bill With In-Office Administration
Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method for...

LEQVIO via Referral to an Alternate Injection Center (AIC)
If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle...

How Do You Get Your Patients Started on LEQVIO?
Watch our experts discuss the benefits of the 3 ways to acquire LEQVIO for patients.
Expert Voices
Watch and learn what the experts have to say about LEQVIO

Patients Who Could Benefit From LEQVIO
Dr Pam Taub and Dr Alan S. Brown describe a few types of patients from their clinics who are struggling to achieve the recommended...

How is LEQVIO Dosing Different From PCSK9 mAbs?
Gain valuable insight from experts as they discuss how LEQVIO dosing differs from PCSK9 mAbs.

What's Different About the Way LEQVIO Lowers LDL Cholesterol Compared to PCSK9 mAbs?
LEQVIO is not another PCSK9 monoclonal antibody. It's something else...

How Do You Explain the Value of LEQVIO to Your Patients?
Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

How Do You Identify Appropriate Patients with ASCVD for LEQVIO?
Follow along with our diverse panel of HCPs as they dive into the keys to identifying patients appropriate for LEQVIO.

How Do You Get Your Patients Started on LEQVIO?
Watch our experts discuss the benefits of the 3 ways to acquire LEQVIO for patients.
THERE'S MORE TO KNOW ABOUT LEQVIO
See how LEQVIO is there to support you and your patients
EXPLORE SUPPORTAND ACCESS

THERE'S MORE TO KNOW ABOUT LEQVIO
See how LEQVIO is there to support you and your patients
EXPLORE SUPPORTAND ACCESS
